Precigen (PGEN) News
NASDAQ: PGENHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.81+0.21 (+2.76%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PGEN news summary
We found 15 recent headlines mentioning Precigen (PGEN): 5 in the past week and 14 in the past 30 days, most often from Nasdaq. For price context, PGEN is up 2.76% at $7.81. The most recent story, "Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal", was published by Nasdaq on Oct 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Precigen headlines
- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.NasdaqNVS, IONS, ACIU, PGEN
- PGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowPrecigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.NasdaqPGEN, MRK, INO
- Novo's Denecimig BLA Review Delayed by FDA Facility Remediation WorkNVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.NasdaqNVO, ALDX, ACIU, PGEN
- The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health CompaniesHealthcare stocks like Abbott Laboratories offer low-beta exposure as rate hike fears and inflation keep markets volatile.NasdaqABT, CORT, BHC, PGEN
- Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in FocusTMO, CRCT and SHOP delivered strong gains as Zacks highlighted standout performers across its research portfolios.NasdaqICE, FAST, DGX, TMO
- 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.NasdaqABT, CORT, BHC, PGEN
- Here's Why You Should Add URGN Stock to Your Portfolio NowUroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.NasdaqURGN, TEVA, ACIU, PGEN
- KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing NearsKodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.NasdaqKOD, REGN, ACIU, PGEN
- Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDVMIRM's brelovitug meets the phase III AZURE-1 goal in chronic hepatitis delta virus, with strong virologic response and ALT normalization rates.NasdaqMIRM, REGN, PGEN
- KROS Begins Dosing in Phase II Study With Rinvatercept in DMDKeros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.NasdaqKROS, REGN, TAK, PGEN
- Vertex Posts Positive Phase II Data on Kidney Disease DrugVRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.NasdaqVRTX, ALDX, ACIU, PGEN
- After Hours Most Active for Sep 16, 2026 : RIG, SLB, IGOV, BSX, CPNG, PGEN, RKT, NU, NVDA, NFLX, QQQ, GRABThe NASDAQ 100 After Hours Indicator is up 12.49 to 28,957.55. The total After hours volume is currently 126,349,072 shares traded.The following are the most active stocks for the after hours…NasdaqRIG, SLB, IGOV, BSX
- Gilead Expands Lenacapavir Access With New PAHO Deal in Latin AmericaGILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.NasdaqGILD, ALDX, ACIU, PGEN
- GSK Inks $750M Deal to Add Experimental Blood Cancer TherapyGSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.NasdaqGSK, ALDX, ACIU, PGEN
- ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Upargenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.NasdaqARGX, ACIU, AMRX, PGEN